Voyager Therapeutics, Inc. announced the appointment of George Scangos, Ph.D., as a director of the Company and as a member of the Science and Technology Committee of the Board, effective May 9, 2023. Dr. Scangos was designated as a Class I director to serve until the 2025 annual meeting of the stockholders of the Company and thereafter until his successor has been duly elected and qualified, or until his earlier death, resignation or removal. Scangos has decades of experience building and leading biopharmaceutical companies, having previously served as CEO of Exelixis, Inc.; Biogen, Inc.; and most recently Vir Biotechnology, Inc. Scangos most recently served as President and CEO of Vir from 2016 to 2023.

Prior to joining Vir, Scangos served as CEO and as a member of the Board of Biogen, Inc. for six years. Previously, he spent 14 years as President and CEO of Exelixis, Inc. Scangos served as Chair of PhRMA in 2016, and as the Chair of the California Healthcare Institute in 2010. He currently serves on the Board of Trustees of Cornell University; the Board of Overseers of the University of California, San Francisco; and the Board of Trustees of Life Science Cares.

Prior to joining industry, Scangos was a Professor of Biology at Johns Hopkins University. He received a B.A. in Biology from Cornell University and a Ph.D. in Microbiology from the University of Massachusetts.